ストックスクリーナーアプリを入手
61.23
1.76%
-1.10
Cytokinetics Inc (CYTK) 最新ニュース
Cytokinetics to Announce Third Quarter Results on November 4, 2026 - GlobeNewswire Inc.
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Form 4 Cytokinetics Inc: Nancy Wysenski (Director) For: 16 October By Investing.com - Investing.com Canada
195 shares replace a cash retainer for Cytokinetics (CYTK) director Edward M. Kaye. - Stock Titan
A 195-share award brings Harrington's direct Cytokinetics (CYTK) holdings to 22,127 shares. - Stock Titan
Cytokinetics Director Wendell Wierenga Purchases 97 Shares at $63.92 Each - Kalkine Media
Shares replace a cash retainer as Cytokinetics (CYTK) director Henderson receives 352 shares. - Stock Titan
Officer Fady Malik proposes selling 16,386 Cytokinetics (CYTK) shares from option exercises. - Stock Titan
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $113 - Moomoo
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
29 new hires at Cytokinetics received stock awards. Share awards vest over 3 years; options over 4. - Stock Titan
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says - www.marketscreener.com
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says - Yahoo Finance
CYTK Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
HC Wainwright & Co. reiterates Buy rating on Cytokinetics, $140 price target - TradingView
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth? - Yahoo Finance
BofA Securities Adjusts Price Target on Cytokinetics to $81 From $85, Maintains Neutral Rating - Yahoo Finance
Canada authorizes a drug for adults whose thickened heart muscle blocks blood flow - Stock Titan
Cytokinetics Announces Health Canada Approval of MYQORZO® - GlobeNewswire
CYTK Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus
William Blair Initiates Coverage on Cytokinetics With Outperform Rating - Yahoo Finance
William Blair initiates Cytokinetics stock coverage with outperform rating By Investing.com - Investing.com South Africa
William Blair initiates Cytokinetics stock coverage with outperform rating - Investing.com
Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today - Benzinga
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK
Cytokinetics Sees Myqorzo Launch Strength Carry Into 2027, RBC Says - marketscreener.com
Cytokinetics (NasdaqGS:CYTK) Stock Forecast & Analyst Predictions - Simply Wall Street
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
UBS cuts Cytokinetics stock price target on valuation, keeps Buy - Investing.com
Cytokinetics Insider Sold Shares Worth $471,600, According to a Recent SEC Filing - Yahoo Finance
A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options. - Stock Titan
Cytokinetics (CYTK), What Is Behind The Fresh Attention? - Yahoo Finance
Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates - Yahoo Finance
Cytokinetics (CYTK) Reports Phase 3 Aficamten Gains In Non Obstructive HCM - Yahoo Finance
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Cytokinetics presents additional aficamten data from trial - Investing.com
Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo. - Stock Titan
Cytokinetics Q2 2026 Earnings Call: Complete Transcript - Benzinga
Cytokinetics EVP Fady Malik sells $214,830 in company stock - Investing.com
Form 4 Cytokinetics Inc For: 11 October By Investing.com - Investing.com Nigeria
CYTK6536068 Bond Yield and Price — FINRA:CYTK6536068 - TradingView
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Cytokinetics Inc (CYTK) EVP Research & Development Fady Malik Se - GuruFocus
Cytokinetics (CYTK): Company Profile, Stock Price, News, Rankings - Fortune
Cytokinetics Falls as Investors Appear to Take Profits Despite Recent Aficamten Progress - Quiver Quantitative
CYTK6536068 Bond Profile: Coupon and Redemption - TradingView
Wells Fargo Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada
Cytokinetics Inc. Advanced Charts | CYTK - Barron's
Cytokinetics Announces Four Presentations at HFSA 2026 Highlighting Aficamten Data in Hypertrophic Cardiomyopathy - Quiver Quantitative
2.17%
1.90%
大文字化:
|
ボリューム (24 時間):